W
Wen Xue
Researcher at University of Massachusetts Medical School
Publications - 101
Citations - 15863
Wen Xue is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Genome editing & Cas9. The author has an hindex of 39, co-authored 90 publications receiving 13365 citations. Previous affiliations of Wen Xue include Cold Spring Harbor Laboratory & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
A microRNA component of the p53 tumour suppressor network
Lin He,Xingyue He,Xingyue He,Lee P. Lim,Elisa de Stanchina,Elisa de Stanchina,Zhenyu Xuan,Yu Liang,Wen Xue,Lars Zender,Jill F. Magnus,Dana Ridzon,Aimee L. Jackson,Peter S. Linsley,Caifu Chen,Scott W. Lowe,Michele A. Cleary,Gregory J. Hannon +17 more
TL;DR: A family of miRNAs, miR-34a–c, whose expression reflected p53 status is described, whose encoded genes are direct transcriptional targets of p53, whose induction by DNA damage and oncogenic stress depends on p53 both in vitro and in vivo.
Journal ArticleDOI
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue,Lars Zender,Cornelius Miething,Ross A. Dickins,Ross A. Dickins,Eva Hernando,Valery Krizhanovsky,Carlos Cordon-Cardo,Scott W. Lowe,Scott W. Lowe +9 more
TL;DR: It is indicated that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.
Journal ArticleDOI
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Lars Zender,Mona S. Spector,Wen Xue,Peer Flemming,Carlos Cordon-Cardo,John Silke,Sheung Tat Fan,John M. Luk,Michael Wigler,Gregory J. Hannon,Gregory J. Hannon,David Mu,Robert Lucito,Scott Powers,Scott W. Lowe,Scott W. Lowe +15 more
TL;DR: A tractable model of liver cancer is established, two oncogenes that cooperate by virtue of their coamplification in the same genomic locus are identified, and an efficient strategy for the annotation of human cancer genes is suggested.
Journal ArticleDOI
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Hao Yin,Wen Xue,Sidi Chen,Roman L. Bogorad,Eric Benedetti,Markus Grompe,Victor Koteliansky,Phillip A. Sharp,Tyler Jacks,Daniel G. Anderson +9 more
TL;DR: In this article, the authors demonstrate CRISPR-Cas9-mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia.
Journal ArticleDOI
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
Hao Yin,Chun-Qing Song,Joseph R. Dorkin,Lihua Julie Zhu,Yingxiang Li,Qiongqiong Wu,Angela I. Park,Junghoon Yang,Sneha Suresh,Aizhan Bizhanova,Ankit Gupta,Mehmet Fatih Bolukbasi,Stephen Walsh,Roman L. Bogorad,Guangping Gao,Zhiping Weng,Yizhou Dong,Victor Koteliansky,Victor Koteliansky,Scot A. Wolfe,Robert Langer,Wen Xue,Daniel G. Anderson +22 more
TL;DR: The delivery strategy is applied to a mouse model of human hereditary tyrosinemia and it is shown that the treatment generated fumarylacetoacetate hydrolase (Fah)-positive hepatocytes by correcting the causative Fah-splicing mutation and rescued disease symptoms such as weight loss and liver damage.